BASF showcases expertise at the CPhI worldwide in Madrid
* New excipient Soluplus makes active pharmaceutical ingredients soluble and bioavailable
* Active drug substance phenylephrine strengthens BASF’s position on global cold remedies market
* Custom synthesis: customized exclusively
* Broad product portfolio of intermediates, inorganics and catalysts
Ludwigshafen , Germany .– BASF is to showcase its extensive expertise at the Convention on Pharmaceutical Ingredients and Intermediates – CPhI worldwide – from October 13 – 15, 2009, Hall 3, Stand 3F24. The organization has once again added to its array of products for pharmaceutical industry customers. This year’s stand is themed “Expertise across the entire pharmaceutical value chain,” and exhibits products and services including active drug substances, excipients, custom synthesis, intermediates, inorganics and catalysts.
Excipients: Soluplus launch
BASF presents its newly developed solubilizing agent Soluplus® for the first time. Soluplus is an innovative pharmaceutical excipient which enhances the solubility of poorly soluble drugs and so increases their bioavailability. Soluplus thus enhances absorption of the drugs in the body. The new product is ideal for innovative process technologies such as melt extrusion. The launch enlarges BASF’s existing range of solubilizing agents.
BASF’s services in the production of medicines encompass the supply of a vast range of high-performance excipients such as binders and disintegrants from the Kollidon® family, coating polymers marketed under the Kollicoat® brand, and numerous other substances, including solubilizing agents. All products are manufactured fully in accordance with cGMP guidelines (cGMP stands for current Good Manufacturing Practice).
Acting pharmaceutical ingredients: consistently high quality
Phenylephrine is a new addition to BASF’s active pharmaceutical ingredient portfolio. The well-established substance combats colds quickly and effectively. The launch is BASF’s response to increased demand for the tried and tested agent. Phenylephrine is particularly popular in the USA, the world’s largest market for cold remedies. BASF supplies generic drug substances for a variety of therapeutic indications. The company is world leader in caffeine, i buprofen, pseudoephedrine and theophylline. Customers world-wide are supplied with consistently high-quality product from a total of six production sites.
Custom synthesis: customized exclusivity
BASF has expanded its capacities in azide chemistry and low temperature reactions, as well as investing in the handling of highly potent compounds. BASF now offers customers more than 130 different methods which are carried out in accordance with strict cGMP requirements in more than 600 cubic meters of flexible multi-product reactors in Germany, France and Switzerland. BASF produces customized active pharmaceutical ingredients and highly advanced intermediates on a confidential and exclusive basis for pharmaceutical manufacturers, and is continually expanding its custom synthesis portfolio. BASF experts support the entire pharmaceutical life cycle – from production on a kilogram scale to commercial manufacture, from the early clinical development stage and market launch right through to generic drug status. The company’s portfolio also includes phosgene chemistry and asymmetric hydrogenation.
BASF has extensive expertise across the entire pharmaceutical value chain
The portfolio also includes a broad variety of intermediate products including building blocks, reagents, solvents and protective groups. Customers benefit from an extensive range of chiral amines, alcohols, epoxides and acids that are marketed under the ChiPros® trademark as well as an extensive technology platform. Also in focus are two environmentally-friendly catalysts from BASF’s NanoSelectTM platform technology for controlled flexibility: the lead-free Pd-based NanoSelect LF 100 and NanoSelect LF 200 catalysts. Characterized by similar activity and selectivity in specific hydrogenation reactions, these new heterogeneous catalysts are an environmentally compatible alternative to Lindlar catalysts. Inorganic specialties such as organozinc-halide reagents, boranes and a wide range of specialty alcoholates complete BASF’s pharmaceutical range. More information is available at www.pharma.basf.com.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.